foxo4-dri senolytic peptide human trial 2024 2025 Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Buy FOXO4 DRI (Proxofim) Senolytic Peptide For Cellular Renewal FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies Senotherapy for chronic lung disease ScienceDirect
Pay in 4 interest-free payments of $7.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19



